Despite decades of research and development of FDA-approved treatment modalities, cancer therapy remains one of the greatest challenges of our time and is frequently met with low efficacy, high treatment resistance and unwanted side effects.
We are devoted to the development of innovative RNA Nanotherapeutics through state-of-the-art RNA nanotechnology of ingenious design and implementation of the unique properties and versatile functions of RNA at a nanometer scale. Significantly, RNA nanotechnology has many advantageous properties that include simultaneous targeting and therapy, high stability, low toxicity and immunogenicity, controlled synthesis and self-assembly, etc. compared to other small molecule and biologics approaches. With the recent increased FDA approvals and broad use of RNA-based vaccines and medicines, we fully anticipate that our technology represents a highly promising next-generation therapy to benefit cancer patient care through better efficacy, fewer unwanted side effects, and improved patient quality of life and treatment compliance.
The patent on this technology (US11,110,182: Multifunctional RNA nanoparticles and methods for treating cancer and therapeutic resistant cancer) has been issued by USPTO on Sept. 7, 2021.
Our Multifunctional RNA Nanoparticles are Designed with Simultaneous Tumor-specific Targeting and Therapy, and have a number of Distinct Advantages compared to Conventional Small Molecules and Biologicals:
ALL RNA Composition
Control synthesis and self-assembly with great manufacturing compatibility.
Unique Therapeutic Target
We are targeting a unique key therapy resistance gene. Our dual therapeutic modules design could also mean less prone to developing treatment resistance.
Tumor-specific Targeting and Low Toxicity
Our RNA nanoparticles target tumors specifically with no apparent toxicity observed in preclinical models and high potential to improve patient quality of life.
High Stability & Long-Lasting Therapeutic Effect
Our RNase-resistant RNA nanoparticles are highly stable and show long-lasting tumor retention and therapeutic effects in vivo, thus, fewer treatments are likely required for patients and better compliance.